Literature DB >> 26049738

The Silence in Hoch et al.'s Commentary about the Rationale for and Objective(s) of Canada's Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers' Dollars.

Heather McDonald1, Cathy Charles, Laurie Elit, Amiram Gafni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26049738     DOI： 10.1007/s40273-015-0297-4

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  4 in total

1.  Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.

Authors:  Amiram Gafni; Stephen Birch
Journal:  Soc Sci Med       Date:  2005-12-01       Impact factor: 4.634

Review 2.  Is there an economic rationale for cancer drugs to have a separate reimbursement review process for resource allocation purposes?

Authors:  Heather McDonald; Cathy Charles; Laurie Elit; Amiram Gafni
Journal:  Pharmacoeconomics       Date:  2015-03       Impact factor: 4.981

3.  Foundations of cost-effectiveness analysis for health and medical practices.

Authors:  M C Weinstein; W B Stason
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

4.  Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?

Authors:  Jeffrey S Hoch; Jaclyn Beca; Mona Sabharwal; Scott W Livingstone; Anthony L A Fields
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981
  4 in total
  1 in total

1.  The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017.

Authors:  Chris Skedgel; Dominika Wranik; Min Hu
Journal:  Pharmacoeconomics       Date:  2018-04       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.